Skip to content
OpenCapital
Get started

Corcept Therapeutics CORT Accrued research and development expenses

Other financials

Income statement

See full
Revenue$164.9M+4.9%
Gross profit$162.0M+4.7%
Operating income-$49.6M-1,552%
Net income-$31.8M-255%
EPS (diluted)-$0.30-276%

Balance sheet

See full
Cash & equivalents$110.0M+21.1%
Total debt$9.6M+41.0%
Total equity$638.0M-6.6%
Total assets$814.9M-3.7%

Cash flow

See full
Operating cash flow-$16.8M-452%
CapEx$201.0K+93.3%
Free cash flow-$17.0M-464%

Valuation

See full
Market cap$8.58B-64.4%
Enterprise value$8.48B-65.0%
P/E181.2×+1.3×
P/S11.2×-24.0×

Profitability

See full
Gross margin98.3%-0.2pp
Operating margin-1.1%-17.2pp
Net margin6.2%-13.4pp
FCF margin15.6%-10.2pp

Returns & leverage

See full
Return on equity7.2%-14.6pp
Debt / equity0×0.0×
Current ratio2.9×-0.2×

Where this comes from

Reported directly by Corcept Therapeutics in its filing.

Tagged under the XBRL concept cort:AccruedClinicalExpensesCurrent.

The official record: Corcept Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Corcept Therapeutics's accrued research and development expenses.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Corcept Therapeutics's accrued research and development expenses?
Corcept Therapeutics (CORT) reported accrued research and development expenses of $34.09M in Q1 2026.
How has Corcept Therapeutics's accrued research and development expenses changed year-over-year?
Corcept Therapeutics's accrued research and development expenses increased by 35.0% year-over-year, from $25.26M to $34.09M.
What is the long-term trend for Corcept Therapeutics's accrued research and development expenses?
Over 5 years (2020 to 2025), Corcept Therapeutics's accrued research and development expenses has grown at a 19.9% compound annual growth rate (CAGR), from $13.7M to $33.95M.